The applications of the radionuclides play a fundamental role in life sciences
and in particular nowadays is becoming an indispensable branch of medical science with
the radionuclides and labeled compounds production for medical applications. The Re-186g
is a negatron-gamma emitter presently used in metabolic radiotherapy with optimal
perspectives to be used in radioimmunotherapy too, thanks to its suitable nuclear properties:
t1/2=90.64 h, main E¿=137 keV, Eß,max=1 071 keV, energy range suitable to treat cancers
with dimensions from few mm to a few cm. The possibility to use this radionuclide for
therapeutic purposes is linked to the possibility to increase its specific activity AS,
substituting the common (n,¿) reaction on Re-185 with the (p,n) or (d,2n) cyclotron
production on W-186 targets, followed by a selective radiochemical separation of the product
in no-carrier-added form from both W target and Ta co-produced radionuclides.
GROPPI Flavia;
BONARDI Mauro;
MANENTI S.;
MARCHETTI M.;
GINI L.;
ABBAS Kamel;
HOLZWARTH Uwe;
SIMONELLI Federica;
2010-01-28
JOHN WILEY & SONS LTD
JRC56478
0362-4803,
https://publications.jrc.ec.europa.eu/repository/handle/JRC56478,
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
